Biogen Inc. (BIIB)
Biogen Inc. (BIIB) Q2 2024 Earnings Call Transcript
Biogen Inc. (BIIB) Q2 2024 Earnings Call Transcript
Biogen (BIIB) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Biogen (BIIB) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Biogen Inc. (BIIB) Q2 Earnings and Revenues Top Estimates
Biogen Inc. (BIIB) came out with quarterly earnings of $5.28 per share, beating the Zacks Consensus Estimate of $4 per share. This compares to earnings of $4.02 per share a year ago.
Drug maker Biogen boosts profit outlook and tops Q2 profit estimate
Biogen Inc.'s stock BIIB rose 1.8% in premarket trading on Thursday after the drug aker boosted its outlook for its adjusted 2024 profit and topped Wall Street's second-quarter profit expectations. The company cited “positive momentum across new product launches such as its Leqembi Alzheimer's medicine, which rang up $40 million in sales in the quarter.
Biogen beats expectations, hikes outlook as Alzheimer's drug Leqembi and other new products gain traction
Biogen reported second-quarter earnings and revenye that topped estimates and hiked its full-year guidance as cost-cutting efforts showed progress and sales of its breakthrough Alzheimer's drug, Leqembi, and other new products came in higher than expected. The biotech company is pinning its hopes on Leqembi and other new products to drive growth as it reduces costs and grapples with declining demand for its multiple sclerosis therapies.
Biogen lifts 2024 profit forecast on hopes of new product launches
Biogen lifted its full-year earnings forecast on Thursday, as the launch of new treatments such as rare disease drug Skyclarys is expected to make up for a market-share loss of its older multiple sclerosis medicines.
Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?
Let's focus on biotech stocks like GSK, VRTX, BIIB, MRNA and REGN, which are scheduled to report this week.
Countdown to Biogen (BIIB) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
Beyond analysts' top -and-bottom-line estimates for Biogen (BIIB), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.
3 Biotech Names With Potential Catalysts By Year End
The huge sector rotation we have seen in the market over the past few weeks has significantly benefited the SPDR® S&P Biotech ETF. If this trend continues, small-cap names within the sector should continue to advance. Today, we look in more detail at three small/mid-cap biotech stocks with potential catalysts that should hit before the end of 2024.
What Awaits Biogen (BIIB) in Q2 Earnings Post Leqembi Setback?
Biogen's (BIIB) sales in the second quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have been hurt by increased competition.
Europe Just Turned Down Biogen's Alzheimer's Drug. Is the Stock One to Avoid, or a Bad News Buy?
Biogen is counting on its Alzheimer's drug, Leqembi, to jumpstart growth -- and sales are progressing in the United States. But European regulators consider the drug too risky.
European drug regulator rejects Alzheimer's treatment Leqembi from Biogen, Eisai
European drug regulators rejected the Alzheimer's treatment Leqembi from Biogen and Eisai, creating another hurdle for the companies as they scramble to boost uptake of the therapy in the U.S. The European Commission, the EU's executive body, has a final say. But it almost always follows the drug regulator's recommendations.
